Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of US-based Trybe Labs.
This strategic move is set to enhance the company's ability to offer whole body testing and personalised healthcare solutions directly to customers.
Additionally, Hims & Hers will be able to support at-home blood draws, providing customers with deeper health insights and allowing providers to access a wide range of biomarkers and data.
This is expected to aid in the early identification of disease risks and facilitate accurate clinical decision-making.
Leveraging blood lancet technology will allow customers to easily test for cardiac risk, hormone levels, stress markers, cholesterol, liver and thyroid function, and prostate health.
The information gathered can then be utilised by healthcare providers on the platform to create personalised treatment plans.
Furthermore, the integration of de-identified lab data will bolster the development of the company's AI initiatives, including MedMatch by Hims & Hers.
This is aimed at advancing the delivery of an AI-powered healthcare experience that provides affordable and quality care tailored to individual needs.
With the addition of at-home lab testing, Hims & Hers’ customers will gain access to detailed health information, enabling providers to recommend customised treatments.
Hims & Hers chief medical officer Dr Patrick Carroll said: “This next generation of healthcare is what we’re building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them.
“Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient. At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect.”
The acquisition of Trybe Labs was funded through Hims & Hers' available cash reserves.
The company has completed the acquisition and anticipates rolling out the new at-home testing services to customers within the next year.
